Pancreatic cancer heterogeneity and response to Mek inhibition

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Cancer Stroma: Friend or Foe?

(2014) Jesse Gore et al.   CANCER CELL

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival

(2014) Berna C. Özdemir et al.   CANCER CELL

Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma

(2014) Andrew D. Rhim et al.   CANCER CELL

Characterizing DNA methylation alterations from The Cancer Genome Atlas

(2014) Daniel J. Weisenberger   JOURNAL OF CLINICAL INVESTIGATION

Cancer heterogeneity: implications for targeted therapeutics

(2013) R Fisher et al.   BRITISH JOURNAL OF CANCER

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men

(2012) S. Kopetz et al.   CLINICAL CANCER RESEARCH

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

(2012) Meredith A. Collins et al.   JOURNAL OF CLINICAL INVESTIGATION

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

(2012) Andrew V. Biankin et al.   NATURE

A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma

(2012) Eric A. Collisson et al.   Cancer Discovery

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice

(2009) Michael P Kim et al.   Nature Protocols

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE